City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  58  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for Brain and Nervous System Cancer:
COH Protocol Number: 17191

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Patient Treatment with Dual Delivery (Intraventricular/Intracavitary) of Cellular Immunotherapy Using Autologous IL13(EQ)BBz/CD19t+ TCM-Enriched T Cells in Addition to Temozolomide for a Patient with Newly Diagnosed Glioblastoma After Completing Radiation and Low Dose Daily Temozomide (UPN 208)

COH Protocol Number: 16190 ClinicalTrials.gov Number: NCT02402244

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

COH Protocol Number: 16062 ClinicalTrials.gov Number: NCT02546102

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase III Randomized Double-blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

COH Protocol Number: 16057 ClinicalTrials.gov Number: NCT02633501

Principal Investigator: Lalit Vora, MD
Sponsor: Industrial

Title:  P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

COH Protocol Number: 14221 ClinicalTrials.gov Number: NCT02176967

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

COH Protocol Number: 14108 ClinicalTrials.gov Number: NCT02192359

Principal Investigator: Jana Portnow, MD
Sponsor: NCI Approved External Peer Review

Title:  A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas

COH Protocol Number: 13384 ClinicalTrials.gov Number: NCT02208362

Principal Investigator: Behnam Badie, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Ra2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma

COH Protocol Number: 13140 ClinicalTrials.gov Number: NCT01096368

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS0831:Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma ages 1-21 years

COH Protocol Number: 08138

Principal Investigator: Ellie Maghami, MD
Sponsor: Institutional

Title:  City of Hope Head and Neck Database Using the American Head and Neck Society Otobase

COH Protocol Number: 01094 ClinicalTrials.gov Number: NCT00256763

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL00B1: Neuroblastoma Biology Studies

The following studies are available for many cancer types, including Brain and Nervous System Cancer:
COH Protocol Number: 17235

Principal Investigator: Jessica Clague dehart, PhD
Sponsor: Institutional

Title:  The Effect of the "Living Well After Cancer" Program on Quality of Life and Metabolic Measures

COH Protocol Number: 17154

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: NCI Approved External Peer Review

Title:  Blood Samples to Identify Biomarkers for Busulfan

COH Protocol Number: 17150 ClinicalTrials.gov Number: NCT03170960

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

COH Protocol Number: 17109 ClinicalTrials.gov Number: NCT03104699

Principal Investigator: Edward Wang, MD
Sponsor: Industrial

Title:  A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

COH Protocol Number: 17012

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  Immunomonitoring of Patients Treated with a P53MVA Vaccine in Combination with Pembrolizumab

COH Protocol Number: 16334

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  Assessment of Cardiovascular Reserve Capacity in Hematopoietic Cell Transplantation Survivors

COH Protocol Number: 16273 ClinicalTrials.gov Number: NCT02890368

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase I Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

COH Protocol Number: 16251 ClinicalTrials.gov Number: NCT03067766

Principal Investigator: Jaroslava Salman, MD
Sponsor: Institutional

Title:  A Pilot Study to Test the Feasibility of Comic Art Creation for Symptom Management in Cancer Supportive Care

COH Protocol Number: 16219

Principal Investigator: Jeffrey Weitzel, MD
Sponsor: NCI Approved External Peer Review

Title:  Understanding How Clients Make Meaning of Their Variants of Uncertain Significance in the Age of Multi-Gene Panel Testing for Cancer Susceptibility

COH Protocol Number: 16166 ClinicalTrials.gov Number: NCT02703571

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination with Trametinib (TMT212) in Patients with Metastatic or Advanced Solid Tumors

COH Protocol Number: 16139 ClinicalTrials.gov Number: NCT01421524

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin’s Lymphoma or Multiple Myeloma

COH Protocol Number: 16130 ClinicalTrials.gov Number: NCT02360215

Principal Investigator: Nayana Vora, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG-CC001: A Randomized Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases

COH Protocol Number: 16124 ClinicalTrials.gov Number: NCT02717507

Principal Investigator: Saro Armenian, DO
Sponsor: Cooperative Group

Title:  COG ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

COH Protocol Number: 16097 ClinicalTrials.gov Number: NCT02517398

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

COH Protocol Number: 15434 ClinicalTrials.gov Number: NCT02465060

Principal Investigator: Karen Reckamp, MD
Sponsor: Cooperative Group

Title:  ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.